Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Prothena Corp Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Prothena Corp Plc, Medical Devices Deals, 2011 to YTD 2017 10
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
MJFF Enters into Agreement with Prothena 12
Licensing Agreements 13
Roche Enters into Licensing Agreement with Prothena 13
Roche Enters Into Licensing Agreement With Prothera 14
Equity Offering 16
Prothena Raises USD155.3 Million in Public Offering of Shares 16
Prothena Raises USD137 Million in Public Offering of Shares 18
Prothena Raises USD122 Million in Public Offering of Shares 20
Prothena Completes Exercise of Underwriter’s Over Allotment Option for Public Offering of Shares for USD123 Million 22
Prothena Completes Public Offering Of Shares For US$92 Million 24
Prothena Corp Plc – Key Competitors 26
Prothena Corp Plc – Key Employees 27
Prothena Corp Plc – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Financial Announcements 29
Nov 07, 2017: Prothena Reports Third Quarter 2017 Financial Results and Provides R&D Update 29
Aug 08, 2017: Prothena Reports Second Quarter 2017 Financial Results and Provides R&D Update 31
May 09, 2017: Prothena Reports First Quarter 2017 Financial Results and Provides R&D Update 33
Feb 14, 2017: Prothena Reports Fourth Quarter and Full Year 2016 Financial Results, and Provides Financial Guidance and R&D Update 35
Nov 01, 2016: Prothena Reports Third Quarter 2016 Financial Results and Provides R&D Update 37
Aug 02, 2016: Prothena Reports Second Quarter 2016 Financial Results; Provides R&D Update 39
May 03, 2016: Prothena Reports First Quarter 2016 Financial Results and Provides R&D Update 41
Feb 18, 2016: Prothena Reports Fourth Quarter and Full Year 2015 Financial Results; Provides Financial Guidance and R&D Update 43
Corporate Communications 45
Jun 12, 2017: Prothena Announces Appointment of Wagner Zago, PhD as Chief Scientific Officer 45
May 16, 2017: Prothena Announces Appointment of Sarah Noonberg, MD, PhD as Chief Medical Officer 46
Oct 03, 2016: Prothena Announces Appointment of Dr. Gene G. Kinney as President, Chief Executive Officer and Director 47
Sep 06, 2016: Prothena Announces Appointment of Gene G. Kinney as Chief Operating Officer 48
Feb 24, 2016: Prothena Announces Appointment of Chief Commercial Officer 49
Product News 50
11/03/2016: Data for Prothena NEOD001 to be Presented at the 58th Annual American Society of Hematology Meeting 50
07/05/2016: Prothena Presents New Data from Phase 1/2 Study of NEOD001 Demonstrating Improvements in Three Organ Systems in Previously-Treated Patients with AL Amyloidosis 52
06/21/2016: Prothena to Present at 15th International Symposium on Amyloidosis Showcasing Broad Commitment to Advancing New Therapies for Systemic Amyloidoses 55
05/23/2016: Prothena to Present Wide Range of Studies on Amyloidosis, Including New Clinical Data on NEOD001, at International Symposium on Amyloidosis 57
02/09/2016: Data From Prothena Ongoing Phase 1/2 Clinical Trial of NEOD001 in AL Amyloidosis Published in the Journal of Clinical Oncology 58
Clinical Trials 60
Sep 18, 2017: Prothena Presents New Research Supporting Clinical Relevance of Cardiac Biomarker NT-proBNP in AL Amyloidosis 60
Aug 15, 2017: Prothena to Present New Research on Cardiac Biomarker NT-proBNP in AL Amyloidosis at HFSA Annual Meeting 62
Apr 02, 2017: Clinical Results Presented from Prothena’s Phase 1b Study of PRX002/RG7935 Demonstrating Robust Antibody CNS Penetration and Significant Reduction of Free Serum Alpha-synuclein in Patients with Parkinson’s Disease 63
Mar 09, 2017: Results for Prothena’s Phase 1b Multiple Ascending Dose Study of PRX002/RG7935 in Patients with Parkinson’s Disease to be Presented at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases 65
Dec 13, 2016: First-In-Human Assessment of PRX002, Prothenas Anti-Alpha Synuclein Antibody for Parkinsons Disease, Published in Movement Disorders Journal 67
Nov 09, 2016: Prothena Reports Results from Phase 1b Study of PRX002 Demonstrating Robust Antibody CNS Penetration and Significant Reduction of Free Serum Alpha-synuclein in Patients with Parkinson’s Disease 68
Mar 16, 2016: Data from Prothena’s Preclinical Program on Conformation-Specific Antibodies Against Misfolded Transthyretin Published in Amyloid 70
Mar 16, 2016: Data from Prothena’s Preclinical Program on Conformation-Specific Antibodies Against Misfolded Transthyretin Published in Amyloid 71
Appendix 72
Methodology 72
About GlobalData 72
Contact Us 72
Disclaimer 72
Prothena Corp Plc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Prothena Corp Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Prothena Corp Plc, Deals By Therapy Area, 2011 to YTD 2017 9
Prothena Corp Plc, Medical Devices Deals, 2011 to YTD 2017 10
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
MJFF Enters into Agreement with Prothena 12
Roche Enters into Licensing Agreement with Prothena 13
Roche Enters Into Licensing Agreement With Prothera 14
Prothena Raises USD155.3 Million in Public Offering of Shares 16
Prothena Raises USD137 Million in Public Offering of Shares 18
Prothena Raises USD122 Million in Public Offering of Shares 20
Prothena Completes Exercise of Underwriter's Over Allotment Option for Public Offering of Shares for USD123 Million 22
Prothena Completes Public Offering Of Shares For US$92 Million 24
Prothena Corp Plc, Key Competitors 26
Prothena Corp Plc, Key Employees 27
Prothena Corp Plc, Subsidiaries 28